+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk

Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk

Mycoses 39(9-10): 329-339

Systemic candidosis is currently a major concern among certain groups of patients at particular risk because of recent treatment modalities. To prevent spread of Candida albicans, in particular, from the orogastrointestinal tract antimycotic treatment would appear beneficial. So far, however, suitable drugs are rare. Polyenes, and in particular oral nystatin, are the main ones considered so far. More recently, the oral azoles have provided therapeutic alternatives. In this review the current role of nystatin and, in particular nystatin tablets, which are better accepted than suspensions at higher dose levels, is described, focusing on efficacy and safety as determined in controlled trials. Recent evidence suggests that oral application of nystatin tablets can be considered both efficacious and safe in the appropriate context. The relative potency of oral nystatin and systemic azoles, particularly ketoconazole and fluconazole, awaits final determination.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 002779680

Download citation: RISBibTeXText

PMID: 9009654

DOI: 10.1111/j.1439-0507.1996.tb00149.x

Related references

Evolution of saliva and serum components in patients with oral candidosis topically treated with Ketoconazole and Nystatin. Acta Odontologica Latinoamericana 11(1): 15-25, 1998

Chemotherapy of chronic mucocutaneous candidosis and systemic candidosis treated by oral ketoconazole. Chemotherapie von Oberflachen , Organ und Systemmykosen I Deutsches Nizoral Symposium: 58-68, 1982

Fluconazole versus nystatin in the treatment of oral candidosis. Acta Odontologica Scandinavica 56(4): 202-205, 1998

Nystatin pastilles and suspension in the treatment of oral candidosis. British Dental Journal 181(6): 209-211, 1996

Comparison of ketoconazole suspension and nystatin in the treatment of newborns and infants with oral candidosis. Mycoses 32(6): 312-315, 1989

Novel Nystatin A₁ derivatives exhibiting low host cell toxicity and antifungal activity in an in vitro model of oral candidosis. Medical Microbiology and Immunology 203(5): 341-355, 2014

Clinical trial: clotrimazole troche vs. itraconazole oral solution in the treatment of oral candidosis in AIDS patients. International Journal of Dermatology 39(11): 859-861, 2000

Clinical profile and risk factors for oral candidosis in sick newborns. Indian Pediatrics 33(4): 299-303, 1996

In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis. Mycoses 54(6): 501-505, 2011

Clinical spectrum of oral candidosis and its role in HIV-infected patients. Mycoses 32(Suppl. 2): 23-29, 1989

Detection of candida circulating antigens value and limits in a longitudinal survey of 80 patients with high risk of systemic candidosis. Bulletin de la Societe Francaise de Mycologie Medicale 17(1): 167-170, 1988

A randomised, double-blind study of itraconazole versus placebo in the treatment and prevention of oral or oesophageal candidosis in patients with HIV infection. International Journal of Clinical Practice 53(5): 349-352, 2000

Oral candidosis as a clinical marker of immune failure in patients with HIV/AIDS on HAART. Aids Patient Care and Stds 19(2): 70-77, 2005

Logistic regression analysis for the risk factors of oral candidosis among patients with non-insulin dependent diabetes mellitus. Hua Xi Kou Qiang Yi Xue Za Zhi 28(1): 41-44, 2010

Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomised clinical trial. Critical Care 16(2): R57, 2012